Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CANAGLIFLOZIN Cause Intestinal obstruction? 11 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Intestinal obstruction have been filed in association with CANAGLIFLOZIN (INVOKANA). This represents 0.1% of all adverse event reports for CANAGLIFLOZIN.

11
Reports of Intestinal obstruction with CANAGLIFLOZIN
0.1%
of all CANAGLIFLOZIN reports
1
Deaths
7
Hospitalizations

How Dangerous Is Intestinal obstruction From CANAGLIFLOZIN?

Of the 11 reports, 1 (9.1%) resulted in death, 7 (63.6%) required hospitalization, and 3 (27.3%) were considered life-threatening.

Is Intestinal obstruction Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CANAGLIFLOZIN. However, 11 reports have been filed with the FAERS database.

What Other Side Effects Does CANAGLIFLOZIN Cause?

Diabetic ketoacidosis (3,413) Toe amputation (2,193) Osteomyelitis (2,146) Acute kidney injury (1,853) Fungal infection (1,385) Gangrene (1,081) Weight decreased (1,014) Cellulitis (1,007) Urinary tract infection (920) Diabetic foot infection (832)

What Other Drugs Cause Intestinal obstruction?

ADALIMUMAB (5,727) VEDOLIZUMAB (1,263) SEMAGLUTIDE (924) INFLIXIMAB (907) RISANKIZUMAB-RZAA (853) BEVACIZUMAB (686) LENALIDOMIDE (504) CLOZAPINE (484) OCTREOTIDE (463) USTEKINUMAB (459)

Which CANAGLIFLOZIN Alternatives Have Lower Intestinal obstruction Risk?

CANAGLIFLOZIN vs CANAGLIFLOZIN\METFORMIN CANAGLIFLOZIN vs CANAKINUMAB CANAGLIFLOZIN vs CANDESARTAN CANAGLIFLOZIN vs CANDESARTAN CILEXETIL CANAGLIFLOZIN vs CANDESARTAN CILEXETIL\HYDROCHLOROTHIAZIDE

Related Pages

CANAGLIFLOZIN Full Profile All Intestinal obstruction Reports All Drugs Causing Intestinal obstruction CANAGLIFLOZIN Demographics